A new system can dial expression of synthetic genes up or down
The promoter editing system could be used to fine-tune gene therapy or to more efficiently reprogram cells for therapeutic use.
The promoter editing system could be used to fine-tune gene therapy or to more efficiently reprogram cells for therapeutic use.
MIT researchers have dramatically lowered the error rate of prime editing, a technique that holds potential for treating many genetic disorders.
Cache DNA has developed technologies that can preserve biomolecules at room temperature to make storing and transporting samples less expensive and more reliable.
Lipid metabolism and cell membrane function can be disrupted in the neurons of people who carry rare variants of ABCA7.
The findings may redefine how cell identity is established and enable the creation of more sophisticated engineered tissues.
The longtime MIT professor and Nobel laureate was a globally respected researcher, academic leader, and science policy visionary who guided the careers of generations of scientists.
Researchers developed a tool to recreate cells’ family trees. Comparing cells’ lineages and locations within a tumor provided insights into factors shaping tumor growth.
Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
A new approach for testing multiple treatment combinations at once could help scientists develop drugs for cancer or genetic disorders.
The approach collects multiple types of imaging and sequencing data from the same cells, leading to new insights into mouse liver biology.
New evidence suggests sensory stimulation of gamma-frequency brain rhythm may promote broad-based restorative neurological health response.
Founded by MIT researchers, Senti Bio is giving immune cells the ability to distinguish between healthy and cancerous cells.
MIT biologists have found that defects in some transfer RNA molecules can lead to the formation of these common conditions.
MIT associate professor recognized for exceptional distinction in teaching, research, and service at MIT.
CAMP4 Therapeutics is targeting regulatory RNA, whose role in gene expression was first described by co-founder and MIT Professor Richard Young.